Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8763109 | 0.98 | CYP11B1 (0.60) | CYP11B1CYP11B2IDO1GAAPKM | |
| SCHEMBL9267101 | 0.88 | CYP11B1 (0.58) | CYP11B1CYP11B2IDO1GAAPKM | |
| SCHEMBL8865733 | 0.86 | CYP11B1 (0.62) | CYP11B1CYP11B2 | |
| SCHEMBL9092547 | 0.84 | CYP11B1 (0.73) | CYP11B1CYP11B2IDO1GAA | |
| SCHEMBL2789863 | 0.84 | CYP11B1 (0.76) | CYP11B1CYP11B2IDO1HPGDSFNTA | |
| Hydrochloric Acid SCHEMBL7847609 | 0.83 | PTGDR2 (0.46) | CYP11B1CYP11B2AKR1B1 | |
| SCHEMBL2786255 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL9092962 | 0.82 | CYP11B1 (0.72) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL7804285 | 0.82 | FNTA (0.50) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL8481395 | 0.82 | CYP11B1 (0.69) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691859-B2 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2010-04-06 | — | — | US | disclosed |
| EP-1382607-B1 | Prenyl transferase inhibitors | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20080176835-A1 | Prenyl Transferase Inhibitors | BIOMEASURE, INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-7361656-B2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-7084135-B1 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2006-08-01 | — | — | US | disclosed |
| US-20060142275-A1 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-06-29 | — | — | US | disclosed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
| WO-1992002257-A2 | RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
| EP-0437103-A2 | Substituted 5-(alkyl)carboxamide imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| EP-0432737-A1 | Cycloheptimidazolone compounds as angiotensin II antagonists for control of hypertension | G.D. Searle & Co. (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0427463-A1 | Substituted N-(imidazolyl)alkyl alanine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176835-A1 | Prenyl Transferase Inhibitors | FNTA, FNTB, RCE1 | CYP11B1 256/4885CYP11B2 266/4885IDO1 3573/4885 |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | CYP11B1 1187/4885CYP11B2 1238/4885IDO1 153/4885 |
| US-20060142275-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | CYP11B1 256/4885CYP11B2 266/4885IDO1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.